奥曲肽联合化疗治疗中晚期肝癌疗效观察  

Effective observation on treating advanced liver cancer with octreotide plus chemotherapy

作　　者：汪明云[1] 魏荣富[1] 顾胤 李双根[1] 胡骏[1] 

机构地区：[1]高淳县人民医院肿瘤内科,江苏高淳211300

出　　处：《现代肿瘤医学》2014年第3期590-593,共4页Journal of Modern Oncology

摘　　要：目的:观察奥曲肽注射液联合化疗治疗中晚期肝癌的疗效。方法:54例中晚期原发性肝癌患者分为两组各27例,对照组用改良FOLFOX化疗方案[奥沙利铂(L-OHP)85mg/m2静脉滴注d1、8;亚叶酸钙(CF)200mg静脉滴注d1-5;5-氟尿嘧啶(5-FU)400mg/m2静脉滴注d1-5],每3周重复;观察组在改良FOLFOX方案的同时加用奥曲肽注射液,奥曲肽注射液0.2mg加5%葡萄糖注射液100-250ml静脉点滴,每日2次,3周为1个周期,每例至少化疗2个周期后评价疗效及毒副反应。根据WHO实体瘤客观疗效评定标准评价疗效,根据KPS评分评价生活质量,采用外周血白细胞和血小板计数评价骨髓毒性。结果:观察组缓解率高于对照组,恶化率低于对照组(P<0.05),总生存期(OS)无显著差异(P>0.05),而在缓解率(ORR)和无病生存期(DFS)方面表现出明显的优势(P<0.05),生活质量提高稳定率高于对照组(P<0.05);对照组外周血白细胞和血小板明显降低(P<0.05)。结论:奥曲肽注射液联合改良FOLFOX方案化疗治疗中晚期肝癌具有改善临床症状、提高生活质量、减少毒副反应等作用,可提高肝癌患者的总病情缓解率和无病生存期。Objective：To explore the effect of octreotide colnbined with FOLFOX for advanced liver cancer. Meth- ods：All 54 patients with advanced liver cancer were divided into two groups. Control group（27 cases） received FOL- FOX regilnen：L - OHP 85mg/m2 ,ivgtt,d1,8 ;CF 200mg,ivgtt,d1-5 ;5 - FU 400mg/m2 ,ivgtt,d1-5. Three weeks were one cycle and the effect and toxieities were evaluated after 2 cycles of ehelnotherapy,3 weeks for one course. Observa- tion group（27 cases） received oetreollde eolnbined with FOLFOX and oetreotide injection 0.21ng plus 5% glucose in- jection 100 - 250ml ivgtt twice a day,3 weeks for one course. WHO response evaluation criteria in solid tumors were used to assess the theraputical effect, KPS was to assess the quality of life, and white blood cell count and platelet count were used to assess the toxicity. Results：The observation group had a higher PR and lower PD than the control group（P 〈 0.05） after the treatlnent. No significant differences were found in OS （P 〉 0.05）. But significant differ- ences were found in overall response rate（ORR） （P 〈 0.05） and disease free survival （DFS） （P 〈 0.05） between the two groups. While in the observation group symptoms were improved better than the control group（P 〈0.05） after the treatment. Comparing with pretreatment,white blood cell count and platelet count showed no significant change in the observation group while decreased in the control group. Conclusion：Octreotide combined with FOLFOX may reliefsymptom and improve quality of life and reduce toxicity,and further improve the overall response rate （ORR） and dis- ease free survival（DFS） of patients with advanced liver cancer.

关 键 词：肝癌 化疗 FOLFOX 奥曲肽注射液 

分 类 号：R735.7[医药卫生—肿瘤]